Addressing Critical Infectious Disease Threats with Targeted Monoclonal Antibody Immunotherapies
Our current monoclonal antibody programs address specific bacterial and viral pathogens. Monoclonal antibodies (mAbs) have the potential to create new ways of preventing and treating serious infections to improve individual outcomes and address the threat of antibiotic resistance. Our expertise lies in applying our deep understanding of infectious disease pathogenesis paired with our ability to access some of the most advanced mAb discovery techniques and platforms available today. We have used this expertise to discover and develop novel mAbs with multiple mechanisms of action and high potency against their intended targets.